Introduction
Methods
Literature search
Study selection
Data extraction
Description of instruments
Results
MOS-HIV
Study | Treatment | Physical health summary | Mental health summary | ||||
---|---|---|---|---|---|---|---|
Mean change | % change | Effect size | Mean change | % change | Effect size | ||
Bucciardini et al. 2007 [13] | ddI/d4T/EFV | 4.7 | 9.4% | −0.43 | 4.0 | 8.2% | −0.40 |
ddI/d4T/NFV | 0.7 | 1.5% | −0.05 | 2.8 | 5.8% | −0.28 | |
ddI/d4T/EFV/NFV | 2.0 | 4.2% | −0.17 | 0.0 | 0.0% | 0.00 | |
Stangl et al. 2007a
[23] | HAART + weekly home visits | 15.0* | 38.3% | −1.53 | 14.2* | 35.5% | −1.27 |
Average for treatment-naïve patients [weighted]
|
2.5
|
0.1
|
−0.55
|
2.3
|
0.1
|
−0.49
| |
Nuesch et al. 2009b
[17] | Continuous treatment | −1.3 | −2.4% | 0.20 | 0.8 | 1.5% | 0.03 |
Scheduled treatment interruptionsc
| −1.2 | −2.2% | 0.19 | 0.4 | 0.8% | −0.15 | |
Huang et al. 2008 [14] | TPV/r (tipranavir / ritonavir) | 0.2 | 0.4% | −0.02 | 1.4 | 2.9% | −0.13 |
CPI/r (boosted comparitor PI) | −0.3 | −0.6% | 0.03 | 1.7 | 3.6% | −0.17 | |
Powers et al. 2006 [18] | Intermittent groupd
| 0.6 | 1.1% | −0.07 | 3.2* | 5.9% | −0.37 |
Continuous groupe
| 1.0 | 1.9% | −0.09 | 3.2 | 5.9% | 0.00 | |
Average for treatment-experienced patients [weighted]
|
−0.2
|
0.0
|
0.04
|
1.5
|
0.0
|
−0.13
| |
Overall mean [weighted]
|
0.7
|
0.1
|
−0.19
|
1.8
|
0.1
|
−0.27
|
Citation | Treatment/dosing regimen | Follow-up period | Physical health summary scores | Mental health summary scores | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Baseline | Follow-up | Significance | Baseline | Follow-up | Significance | |||||
Mean (SD) | Mean | Over time | Between groups | Mean (SD) | Mean | Over time | Between groups | |||
Randomized controlled trials
| ||||||||||
Chang et al. (2007) | Intervention: while receiving individualized acupuncture treatments prescribed by their acupuncturists, listened to tapes with instructions to elicit the relaxation response via earphones, followed by soft music played in the clinic | 4 weeks | 57.5 (21.1) | 61.3 | N | N | 57.5 (17.0) | 62.9 | Y | N |
8 weeks | 62.7 | N | N | 62.8 | N | N | ||||
12 weeks | 65.6 | Y | N | 68.1 | Y | N | ||||
Control: while receiving individualized acupuncture treatments prescribed by their acupuncturists, listened to soft music played in the clinic | 4 weeks | 62.0 (21.4) | 66.7 | N | N | 64.1 (17.9) | 71.0 | Y | N | |
8 weeks | 66.4 | N | N | 69.5 | N | N | ||||
12 weeks | 65.7 | N | N | 70.7 | N | N | ||||
Bucciardini et al. (2007) | Didanosine + stavudine + efavirenz | 1 year | 50 (11) | 54.7 | N | N | 49 (10) | 53.0 | N | N |
2 years | 54.9 | N | N | 50.4 | N | N | ||||
3 years | 54.9 | N | N | 49.5 | N | N | ||||
Didanosine + stavudine + nelfinavir | 1 year | 46 (13) | 46.7 | N | N | 48 (10) | 50.8 | N | N | |
2 years | 49.2 | N | N | 51.5 | N | N | ||||
3 years | 50.9 | N | N | 53.5 | N | N | ||||
Didanosine + stavudine + efavirenz + nelfinavir | 1 year | 48 (12) | 50.0 | N | N | 50 (9) | 50.0 | N | N | |
2 years | 48.1 | N | N | 49.5 | N | N | ||||
3 years | 50.0 | N | N | 53.4 | N | N | ||||
Huang et al. (2008) | Tipranavir + ritanovir | 48 weeks | 48.0 (11.3) | 48.2 | NM | N | 47.8 (10.5) | 49.2 | NM | N |
Boosted comparitor protease inhibitor | 48 weeks | 47.1 (10.9) | 46.8 | NM | N | 46.9 (10.3) | 48.6 | NM | N | |
Lafaurie et al. (2008) | Maintenance of a stable protease inhibitor-containing regimen | 48 weeks | NR | −1.04 | NM | N | NR | 0.00 | NM | N |
Switch to efavirenz + didanosine + emtricitabine once-daily | 48 weeks | NR | −1.76 | NM | N | NR | 1.01 | NM | N | |
Sprinz et al. (2006) | Immediate substitution with lopinavir/ritonavir 400/200 mg twice daily | 4 weeks | 49.44 | 52.06 | Y | Y | 46.7 | 50.79 | Y | Y |
8 weeks | 52.38 | Y | Y | 51.34 | Y | Y | ||||
Deferred (week 4) substitution with lopinavir/ritonavir 400/100 mg twice daily | 4 weeks | 50.32 | 49.71 | N | Y | 48.25 | 48.03 | N | Y | |
8 weeks | 51.12 | N | Y | 50.02 | Y | Y | ||||
Nuesch et al. (2009) | Continuous treatment | 24 weeks | 53.8 (6.6) | 52.7 | N | N | 51.7 (7.6) | 52.7 | Y | Y |
48 weeks | 52.5 | N | N | 52.5 | Y | Y | ||||
CD4-guided scheduled treatment interruption (CD4 threshold of 350 cells/μL for interruption/re-initiation of ARV therapy) | 24 weeks | 54.4 (6.3) | 53.2 | N | N | 49.1 (8.3) | 48.1 | Y | Y | |
48 weeks | 53.2 | N | N | 49.5 | Y | Y | ||||
Powers et al. (2006) | Intermittent treatment (7 cycles of 4 weeks off/8 weeks on HAART) | 4 weeks | 54.2 (8.3) | 54.2 | N | Y | 54.0 (8.8) | 53.56 | N | Y |
12 weeks | 55.55 | N | Y | 57.45 | Y | Y | ||||
40 weeks | 54.76 | N | Y | 57.22 | Y | Y | ||||
Continuous treatment (continue regimen for 22 weeks) | 4 weeks | 53.0 (11.5) | 53.27 | N | Y | 53.8 (15.7) | 53.36 | N | Y | |
12 weeks | 52.97 | N | Y | 57.25 | N | Y | ||||
40 weeks | 54.00 | N | Y | 57.02 | N | Y | ||||
Wu et al. (2006) | Disease Management Assistance System + education | 6 months | 45.7 (11.0) | 44.2 | NR | Y | 49.2 (10.3)* | 49.5 | NR | N |
Education only | 6 months | 41.2 (12.7) | 47.0 | NR | Y | 40.7 (12.4)* | 44.9 | NR | N | |
Non-randomized controlled trials
| ||||||||||
Shalit et al. (2007) | Enfuvirtide + ARTs | 12 weeks | NR | 2.21 | Y | N/A | NR | 2.91 | Y | N/A |
Levine et al. (2008) | Epoetin alfa + iron supplementation (in addition to current ART regimen) | MPD1 | 38.5 (12.0) | 43.0 | N | N/A | 42.4 (11.2) | 47.8 | N | N/A |
24 weeks | 43.5 | Y | N/A | 47.5 | Y | N/A | ||||
Stangl et al. (2007) | HAART and weekly home visits by study staff that re-supplied HAART and other drugs, conducted a pill count, and assessed participants’ health | 3 months | 39.2 (9.8) | 50.6 | Y | N/A | 40.0 (11.2) | 50.2 | Y | N/A |
6 months | 53.0 | Y | N/A | 53.0 | Y | N/A | ||||
9 months | 53.6 | Y | N/A | 54.2 | Y | N/A | ||||
12 months | 54.2 | Y | N/A | 54.2 | Y | N/A |
Randomized controlled trials
Non-randomized controlled trials
EQ-5D
EQ-5D dimension | Mean change | % change | Effect size |
---|---|---|---|
Mobility | −0.4 | −26.67% | −0.4 |
Self-care | −0.2 | −16.67% | −0.3 |
Usual activities | −0.4 | −23.53% | −0.5 |
Pain/discomfort | −0.3 | −17.65% | −0.3 |
Anxiety/depression | −0.5 | −26.32% | −0.4 |